Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787156 | 0.83 | TSHR (0.44) | HSD17B10TSHRL3MBTL1GAATBXAS1 | |
| SCHEMBL22787155 | 0.82 | L3MBTL1 (0.47) | TSHRL3MBTL1GAAALDH1A1 | |
| SCHEMBL22773635 | 0.79 | MAPT (0.51) | HSD17B10TSHRL3MBTL1GAAPPARA | |
| SCHEMBL26983245 | 0.76 | TBXA2R (0.46) | TSHRPPARATBXA2RLTB4RALDH1A1 | |
| SCHEMBL445511 | 0.74 | L3MBTL1 (0.76) | HSD17B10L3MBTL1GAAPPARAALDH1A1 | |
| SCHEMBL24700024 | 0.73 | KMT2A (0.39) | GAAALDH1A1 | |
| SCHEMBL22773529 | 0.72 | CYP4F2 (0.43) | TSHRL3MBTL1GAAPPARA | |
| SCHEMBL2186123 | 0.70 | L3MBTL1 (0.49) | L3MBTL1RXRAGRIN1GRIN2B | |
| SCHEMBL22787166 | 0.70 | LTB4R (0.40) | HSD17B10TSHRL3MBTL1LTB4RALDH1A1 | |
| SCHEMBL2213052 | 0.69 | L3MBTL1 (0.79) | HSD17B10TSHRL3MBTL1GAAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-08-25 | — | — | US | disclosed |
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-08-25 | — | — | US | disclosed |
| WO-2020248065-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | AADAC, ACSL3, ACSL1 | HSD17B10 31/4885TSHR 4504/4885L3MBTL1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.